

1 **Serum asymmetric dimethyl arginine level correlates with the progression and**
2 **prognosis of amyotrophic lateral sclerosis**

3

4 Kensuke Ikenaka¹, Yasuhiro Maeda², Yuji Hotta³, Seiichi Nagano¹, Keita Kakuda¹,
5 Harutsugu Tatebe^{4,5}, Naoki Atsuta^{6,7}, Daisuke Ito⁶, Cesar Aguirre¹, Yasuyoshi Kimura¹,
6 Kousuke Baba¹, Masahisa Katsuno⁶, Takahiko Tokuda^{4,5}, Kazunori Kimura³, Gen
7 Sobue^{8,9}, and Hideki Mochizuki¹

8

9 ¹ Department of Neurology, Osaka University Graduate School of Medicine, Suita,
10 Japan

11 ² Center for Joint Research Facilities Support, Fujita Health University, Toyoake, Japan

12 ³ Department of Hospital Pharmacy, Nagoya City University Graduate School of
13 Pharmaceutical Sciences, Nagoya, Japan

14 ⁴ T & T Brothers Corporation, Chiba, Japan

15 ⁵ National Institutes for Quantum and Radiological Science and Technology (QST),
16 Chiba, Japan

17 ⁶ Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya,
18 Japan

19 ⁷ Department of Neurology, Aichi Medical University School of Medicine, Nagakute,

20 Japan

21 ⁸ Research Division of Dementia and Neurodegenerative Disease, Nagoya University

22 Graduate School of Medicine, Nagoya, Japan

23 ⁹ Aichi Medical University, Nagakute, Japan

24

25 **Corresponding Author:**

26 Kensuke Ikenaka

27 Department of Neurology

28 Osaka University Graduate School of Medicine

29 2-2 Yamadaoka, Suita 565-0871, Japan

30 Phone: +81-6-6879-3571

31 E-mail: ikenaka@neuro1.med.osaka-u.ac.jp

32

33 **Word count: 2167**

34 **Abstract**

35 **Objective:** To investigate the association between serum asymmetric dimethylarginine
36 (ADMA) levels and the progression and prognosis of amyotrophic lateral sclerosis
37 (ALS), and to compare cerebrospinal fluid (CSF) and serum ADMA levels with other
38 biomarkers of ALS.

39 **Methods:** Serum ADMA levels of patients with sporadic ALS (n = 68) and disease
40 control patients (n = 54) were measured using liquid chromatography-tandem mass
41 spectrometry. Serum samples were obtained at the time of patient registration for
42 diagnosis. Correlations of ADMA level and other markers (nitric oxide [NO] and
43 neurofilament light chain [NFL] levels) were analyzed. Changes in the ALS Functional
44 Rating Scale–Revised (ALSFRS-R) score from the onset of disease (ALSFRS-R
45 preslope) was used to assess disease progression. Survival was evaluated using the Cox
46 proportional hazards model and Kaplan–Meier analysis.

47 **Results:** The concentration of ADMA in CSF was substantially higher in patients with
48 ALS than in disease controls. Serum ADMA level correlated with CSF ADMA level (r
49 = 0.591, $p < 0.0001$), and was independently associated with the ALSFRS-R preslope (r
50 = 0.505, $p < 0.0001$). Patients with higher serum ADMA levels had less favorable

51 prognoses. CSF ADMA level significantly correlated with CSF NfL level ($r = 0.456$, p
52 $= 0.0002$) but not with NO level ($r = 0.194$, $p = 0.219$).

53 **Conclusion:**

54 ADMA level is an independent biomarker of ALS disease progression and prognosis,
55 and reflects the degree of motor neuron degeneration. The increased ADMA level in
56 ALS patients was not associated with the inhibition of NO production.

57 (247 words)

58

59 **Abbreviations:** ADL = activities of daily living; ADMA = asymmetric dimethyl
60 arginine; ALS = amyotrophic lateral sclerosis; ALSFRS-R = ALS Functional Rating
61 Scale-Revised; CI = confidence interval; CK = creatinine kinase; CSF = cerebrospinal
62 fluid; FVC = forced vital capacity; HR = hazard ratio; MMT = manual muscle testing;
63 NfL = neurofilament light chain; TPPV = tracheostomy positive pressure ventilation

64 **Introduction**

65 Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized
66 by the selective loss of upper and lower motor neurons. Despite decades of research into
67 the molecular mechanisms underlying the pathogenesis of ALS and the development of
68 molecular targeting therapy, to date, only a few drugs have been shown to be effective
69 for ALS. One of the difficulties in performing clinical trials for ALS patients is the large
70 variation in the clinical courses of the patients^{1 2}, as evaluated by survival time or the
71 revised ALS Functional Rating Scale (ALSFRS-R). To obtain better patient
72 stratification and more reliable measures for monitoring the therapeutic effects of
73 potential treatments, it is imperative to develop biomarkers that accurately reflect the
74 pathophysiology and predict the progression and prognosis of ALS.

75 We recently reported that protein arginine dimethylation is upregulated in the spinal
76 cord of patients with amyotrophic lateral sclerosis (ALS), and that cerebrospinal fluid
77 (CSF) levels of asymmetric dimethylarginine (ADMA) can be a biomarker of ALS
78 disease progression and prognosis³. We hence hypothesized that increased CSF ADMA
79 levels might reflect the hypermethylation of RNA-binding proteins in the spinal motor
80 neurons and surrounding glial cells of ALS disease patients. Interestingly, recent reports
81 have shown that RNA-binding proteins that are targets of arginine dimethylation

82 demonstrate abnormal aggregation or mislocalization in the motor neurons of sporadic
83 ALS (SALS) patients⁴⁻⁷, indicating the involvement of abnormal arginine dimethylation
84 in the pathogenesis of ALS.

85 In this study, we analyzed the changes in serum ADMA levels in ALS patients
86 and the correlation of ADMA level with neurofilament light chain (NfL) level, to
87 understand how ADMA is associated with the pathology of ALS. We also analyzed the
88 correlation between ADMA and nitric oxide (NO) levels in the CSF to determine
89 whether increased ADMA affects ALS pathology through the suppression of NO
90 synthesis. Moreover, towards clinical application, we analyzed the usefulness of serum
91 ADMA level for predicting disease progression and prognosis.

92

93 **Materials and methods**

94 **Patient registry and follow-up**

95 Patients who were diagnosed as having ALS at Osaka University between July 2016 and
96 August 2020 were prospectively enrolled. The data were collected from the patients
97 agreed to participate in the Osaka University Longitudinal Biomarker Study for
98 Neuromuscular Diseases. In total, 68 ALS patients with definite, probable, probable
99 laboratory-supported, or possible ALS according to the revised El Escorial criteria were

100 included. The included patients were registered in the Osaka University Longitudinal
101 Biomarker Study for Neuromuscular Diseases with written informed consent. The
102 clinical scores listed below were obtained for the diagnosis of ALS. Muscle strength
103 was manually tested and scored using the scale of the Medical Research Council
104 (manual muscle testing [MMT]). Disease onset was defined as when the patients
105 became initially aware of muscle weakness or the impairment of swallowing, speech, or
106 respiration. The Japanese version of the ALS Functional Rating Scale-Revised
107 (ALSFRS-R)² was used as a scale to evaluate ADL. The reliability of the Japanese
108 version of the ALSFRS-R has been confirmed previously⁸. To evaluate the functional
109 decline in the ALSFRS-R, we calculated the slope, defined as (decrease in the value
110 within a duration)/duration. The preslope was used to evaluate the decline in the
111 ALSFRS-R from the time of onset to diagnosis (registration), and was calculated as
112 $\text{ALSFRS-R preslope} = (\text{ALSFRS-R at registration} - 48) / (\text{duration from onset to}$
113 $\text{diagnosis})$. The primary endpoint was defined as either the introduction of tracheostomy
114 positive pressure ventilation (TPPV) or death of the patient, and the time a patient
115 reached the primary endpoint was determined by telephone follow-up. TPPV-free
116 survival was defined as survival in the TPPV cases.

117

118 **Clinical data of ALS and control patients**

119 The average age at registration (ALS, 59.6 [46.9–72.3] years and controls, 62.0
120 [48.5–71.5] years) and sex ratio were not significantly different between patients with
121 ALS and controls; sex ratio [male: female]: ALS, 41: 27 and controls, 32: 22). The
122 average duration from onset to registration (months) in patients with ALS was 21.1
123 (5.12–37.1), the average ALSFRS-R at registration was 38.7 (32.5–44.9), and the
124 average %forced vital capacity (FVC) at registration was 84.9% (63.0%—106.8%),
125 which are consistent with previous studies^{2,9-11}. At the end of this study, 23 patients
126 reached the primary endpoint, and the average duration from registration to the primary
127 endpoint was 18.9 months. Regarding disease form (initial symptoms), 13 patients
128 showed the bulbar form, and 55 patients showed the spinal form. The disease controls
129 included 54 patients with Parkinson disease (n = 10), Parkinson syndrome (n = 9),
130 polyneuropathy (n = 7), multiple sclerosis (n = 6), myositis (n = 6), brain infarction (n =
131 5), dystonia (n = 3), and others (n = 8).

132

133 **Measurement of arginine analogs**

134 Arginine, NG, and NG-dimethyl L-arginine (ADMA) were used to construct standard
135 curves (Enzo Life Sciences). ADMA-d6 was prepared according to the method of

136 Kennedy et al.¹². ADMA was measured using a high-performance liquid
137 chromatography-tandem mass spectrometry system (Quattro Premier XE Mass
138 Spectrometer; Waters Corporation, Milford, MA, USA). A 5- μ L sample solution that
139 was deproteinated by methanol was injected into an Intrada Amino Acid column (2 \times 50
140 mm; Imtakt, Kyoto, Japan) at 40 °C. Chromatography was performed at a flow rate of
141 0.6 mL/min using a step gradient alternating between a mixture of acetonitrile:
142 tetrahydrofuran: 25 mmol/L aqueous ammonium formate: formic acid (9: 25: 16: 0.3)
143 and a mixture of 100 mmol/L aqueous ammonium formate: acetonitrile (80: 20). ADMA
144 was analyzed using the multiple reaction monitoring mode of tandem mass
145 spectrometry in positive ion mode. The cone voltage was 22–25 V, collision energy was
146 13–22, and transitions were m/z 203 \rightarrow 46 for ADMA.

147

148 **Quantification of plasma and CSF NfL concentrations**

149 The concentrations of plasma and CSF NfL were quantified as previously described^{13,14},
150 using Simoa NF-light Advantage Kit and a Simoa HD-1 analyzer according to the
151 manufacturer's protocol (Quanterix, Lexington, MA, USA). All samples were analyzed
152 in duplicate.

153

154 **Measurement of NO concentration**

155 The nitrite concentration in the CSF was measured using the nitrite assay kit following
156 the manufacturer's instructions (BioVision, Milpitas, CA, USA). Absorbance at 540 nm
157 was measured using a microplate reader.

158

159 **Statistical analysis**

160 Pearson's correlation analysis was performed to analyze the correlation between factors.

161 Survival time was defined as the time from disease onset to death or the introduction of
162 TPPV. The Kaplan-Meier method was used to estimate survival curves, and the survival
163 curves of the two groups were compared using the logrank test. The Cox proportional
164 hazard model, which included the ALSFRS-R slope at registration and serum ADMA
165 level (ng/mL), was applied to analyze the effects of these variables on survival time.

166 The hazard ratio (HR) and 95% confidence interval (CI) were estimated. Multivariate
167 regression analyses with stepwise variable selection ($\alpha = 0.05$ for inclusion, and
168 $\alpha = 0.10$ for exclusion) was also performed to analyze the effect of ADMA on
169 ALSFRS-R. Statistical Package for the Social Sciences 23.0J software (IBM Japan,
170 Tokyo, Japan) was used to perform statistical analyses.

171

172 **Ethics statement**

173 This study was conducted in accordance with the Declaration of Helsinki and the
174 Ethical Guidelines for Medical and Health Research Involving Human Subjects
175 endorsed by the Japanese government. The Ethics Committee of Osaka University
176 Graduate School of Medicine approved the study (Approval number; 19089-3). All the
177 patients, including disease controls, were informed about this study and written consent
178 have been obtained.

179

180 **Results**

181 **Serum ADMA level is increased in ALS patients and correlates with disease**
182 **progression**

183 We first compared ADMA levels in the serum and CSF, and found that serum ADMA
184 level significantly correlated with CSF level (Figure 1A, $r = 0.591$, $p < 0.032$). Similarly
185 to the increase in CSF ADMA level that we found in our previous study, serum ADMA
186 level was also significantly higher in ALS patients than in disease controls (Figure 1B, p
187 $= 0.002$). Serum ADMA level more strongly correlated with disease progression
188 (ALSFRS-R preslope) (Figure 1C, $r = 0.505$, $p < 0.0001$) than disease severity at each

189 timepoint (ALSFRS-R) (Figure 1D, $r = -0.261$, $p = 0.032$). More importantly,
190 multivariate linear regression analysis demonstrated that among serum ADMA, age, sex,
191 MMT, %FVC, and ALSFRS-R, only serum ADMA was an independent factor that was
192 associated with disease progression (Table 1).

Table 1. Multivariate linear regression analysis with stepwise variable selection; comparison among serum ADMA and clinical ALS parameters		
	ALSFRS-R preslope	
	Coefficient (95% CI)	<i>p</i>-value
Serum ADMA	0.004 (0.000 – 0.006)	< 0.0001
Age	-0.001 (-0.009 – 0.007)	0.775
Sex	0.043 (-0.171 – 0.256)	0.692
MMT	0.014 (-0.003 – 0.032)	0.102
%FVC	-0.005 (-0.010 – 0.001)	0.110
ALSFRS-R	-0.033 (-0.058 – 0.009)	0.009

193

194 **Associations between serum ADMA levels and other biomarkers**

195 Moreover, we measured plasma NfL levels to analyze the degree of neurodegeneration
196 in patients, and found that ADMA level strongly correlated with NfL level (Figure 2A, r
197 $= 0.430$, $p = 0.002$). Interestingly, ADMA level did not correlate with NO level (Figure
198 2B, $r = 0.270$, $p = 0.080$), indicating that the increase in ADMA level was independent
199 of NO dysregulation. Multivariate linear regression analysis demonstrated that among
200 serum ADMA, creatinine, albumin, NO, and plasma NfL level, serum ADMA level was
201 independently associated with disease progression (Table 2).

Table 2. Multivariate linear regression analysis with stepwise variable selection; comparison among serum ADMA and other biomarkers.

	ALSFRS-R preslope	
	Coefficient (95% CI)	<i>p</i> -value
Serum ADMA	0.006 (0.001–0.011)	0.024
Creatinine	-0.536 (-1.255 – 0.183)	0.139
Albumin	-0.30 (-0.429 – 3.69)	0.880
Nitric oxide	-0.003 (-0.048 – 0.041)	0.878
Plasma NFL	0.002 (0.000 – 0.004)	0.045

202

203 **Serum ADMA is a prognostic marker for ALS**

204 Next, we performed multivariate Cox regression analysis of survival time, and found
 205 that serum ADMA level can predict the survival of patients independently of the
 206 ALSFRS-R preslope (Table 3).

Table 3. Multivariate Cox regression analysis of the survival of ALS patients, with adjustments of covariates

	Primary endpoint	
	HR (95% CI)	<i>p</i> -value
Serum ADMA	1.008 (1.000 – 1.016)	0.040
ALSFRS-R preslope	4.368 (1.771 – 10.771)	0.001
n = 68 (23 subjects reached the primary endpoint and 38 subjects were censored)		

207

208 We then analyzed the optimal cutoff score of ADMA level for predicting the prognosis

209 of ALS. When we used a cutoff of ADMA > 110.53 ng/mL, the HR was 4.289 (95% CI:
210 1.642–11.235, $p = 0.003$). We divided the registered patients into two categories using
211 this cutoff score. Figure 3A shows the Kaplan–Meier curves for the primary endpoint of
212 patients in the two categories. The difference between the curves was statistically
213 significant by the logrank test ($p = 0.001$).

214

215 **Discussion**

216 In this study, we showed that serum ADMA level is well correlated with CSF ADMA
217 level and is useful for evaluating ALS disease progression and prognosis, similarly to
218 what we previously reported for CSF ADMA¹⁵. Interestingly, ADMA level correlates
219 more strongly with the ALSFRS-R slope than the ALSFRS-R. This suggests that unlike
220 the decrease in creatinine level, which simply reflects decreased muscle volume and is
221 hence just a consequence of ALS symptoms, the increase in ADMA level more
222 accurately reflects the disease state of patients. Indeed, we showed that serum ADMA
223 level correlates with plasma NfL level, which reflects axonal degeneration and is a
224 pathological biomarkers for ALS^{13, 14, 16–20}.

225 Here we showed that serum ADMA level is increased in ALS patients and is
226 associated with disease progression score (ALSFRS-R slope) independently of several

227 clinical scores and blood biomarkers, including plasma NfL. Serum ADMA level also
228 predicts disease prognosis independently of the ALSFRS-R slope. We used the
229 ALSFRS-R slope only as a coanalysis factor, because the number of patients who
230 reached the primary endpoint (death or the use of an invasive respiratory machine) was
231 only 23 among the 68 participants. Nevertheless, considering that the ALSFRS-R slope
232 is one of the most reliable clinical predictors of prognosis at diagnosis, our data
233 demonstrated that serum ADMA level may be a useful biomarker to predict the
234 prognosis of ALS.

235 In our previous study, we mainly focused on the ADMA/L-arginine ratio,
236 considering that ADMA competes with nitric oxide synthase for binding to L-arginine
237 and inhibits the production of NO. In the present study, we directly measured ADMA
238 instead of its ratio with L-arginine, because we found that ADMA level did not correlate
239 with CSF NO. Our findings suggested that a high ADMA level may reflect ALS
240 pathology independently of the insufficient production of NO, and may shed light on the
241 importance of the hypermethylation of arginines within RNA-binding proteins in the
242 pathogenesis of SALS. Moreover, considering that serum ADMA level is about ten
243 times higher than that of CSF ADMA level, systemic hypermethylation could be the
244 primary change and affects the pathology of the central nervous system in ALS patients.

245 This study has some limitations and bias. First, the number of patients who
246 reached the primary endpoint was small, so the analysis of prognosis was statistically
247 weak. Second, the pathomechanism by which an increased ADMA level affects disease
248 progression remains unclear. Further studies are required to confirm that arginine
249 hyperdemethylation is directly involved in the pathogenesis of ALS, and to determine
250 whether ADMA can be a useful biomarker for clinical applications.

251

252 **COMPETING INTERESTS:** The authors have no conflicts of interest to declare.

253

254 **FUNDING:** This work was supported by the Kanae Foundation for the Promotion of
255 Medical Science and Japan Agency for Medical Research and Development (grant no.
256 JP21wm0425013).

257

258 **Author contributions:**

259 KI, NA, MK, HM, and GS designed the experiments. YM, YH, and KK performed the
260 arginine analysis by liquid chromatography-tandem mass spectrometry. HT and TT
261 performed the neurofilament light chain (NfL) measurements. KI, SN, YK, and KB
262 collected the blood and cerebrospinal fluid (CSF) samples and clinical data. KI

263 performed the statistical analysis. KI, NA, DI, CA, TT, MK, GS, and HM discussed the
264 results and wrote the manuscript. All authors read and approved the final manuscript.

265 **References**

- 266 1. Chio A, Calvo A, Moglia C, Mazzini L, Mora G. Phenotypic heterogeneity of
267 amyotrophic lateral sclerosis: a population based study. *Journal of neurology,*
268 *neurosurgery, and psychiatry* 2011;82(7):740-6.
- 269 2. Watanabe H, Atsuta N, Hirakawa A, Nakamura R, Nakatochi M, Ishigaki S, et al. A
270 rapid functional decline type of amyotrophic lateral sclerosis is linked to low
271 expression of TTN. *Journal of neurology, neurosurgery, and psychiatry*
272 2016;87(8):851-8.
- 273 3. Ikenaka K, Atsuta N, Maeda Y, Hotta Y, Nakamura R, Kawai K, et al. Increase of
274 arginine dimethylation correlates with the progression and prognosis of ALS.
275 *Neurology* 2019;92(16):e1868-e77.
- 276 4. Furukawa Y, Tokuda E. Aggregation of FET Proteins as a Pathological Change in
277 Amyotrophic Lateral Sclerosis. *Advances in experimental medicine and biology*
278 2017;925:1-12.
- 279 5. Tanikawa C, Ueda K, Suzuki A, Iida A, Nakamura R, Atsuta N, et al. Citrullination
280 of RGG Motifs in FET Proteins by PAD4 Regulates Protein Aggregation and
281 ALS Susceptibility. *Cell reports* 2018;22(6):1473-83.
- 282 6. Tyzack GE, Luisier R, Taha DM, Neeves J, Modic M, Mitchell JS, et al. Widespread
283 FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis.
284 *Brain : a journal of neurology* 2019;142(9):2572-80.
- 285 7. Ikenaka K, Ishigaki S, Iguchi Y, Kawai K, Fujioka Y, Yokoi S, et al. Characteristic
286 Features of FUS Inclusions in Spinal Motor Neurons of Sporadic Amyotrophic
287 Lateral Sclerosis. *Journal of neuropathology and experimental neurology*
288 2020;79(4):370-77.
- 289 8. Atsuta N, Watanabe H, Ito M, Nakamura R, Senda J, Kato S, et al. [Development of a
290 telephone survey system for patients with amyotrophic lateral sclerosis using the
291 ALSFRS-R (Japanese version) and application of this system in a longitudinal
292 multicenter study]. *Brain and nerve = Shinkei kenkyu no shinpo*
293 2011;63(5):491-6.
- 294 9. Rosenbohm A, Nagel G, Peter RS, Brehme T, Koenig W, Dupuis L, et al.
295 Association of Serum Retinol-Binding Protein 4 Concentration With Risk for
296 and Prognosis of Amyotrophic Lateral Sclerosis. *JAMA neurology*
297 2018;75(5):600-07.
- 298 10. Shimizu T, Bokuda K, Kimura H, Kamiyama T, Nakayama Y, Kawata A, et al.
299 Sensory cortex hyperexcitability predicts short survival in amyotrophic lateral
300 sclerosis. *Neurology* 2018;90(18):e1578-e87.

- 301 11. Nakamura R, Atsuta N, Watanabe H, Hirakawa A, Ito M, Senda J, et al. Neck
302 weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis
303 patients. *Journal of neurology, neurosurgery, and psychiatry*
304 2013;84(12):1365-71.
- 305 12. Kennedy KJ, Simandan TL, Dix TA. A facile route to cyclic and acyclic
306 alkyl-arginines. *Synthetic Commun* 1998;28(4):741-46.
- 307 13. Shinomoto M, Kasai T, Tatebe H, Kondo M, Ohmichi T, Morimoto M, et al. Plasma
308 neurofilament light chain: A potential prognostic biomarker of dementia in adult
309 Down syndrome patients. *PloS one* 2019;14(4):e0211575.
- 310 14. Kasai T, Kojima Y, Ohmichi T, Tatebe H, Tsuji Y, Noto YI, et al. Combined use of
311 CSF NfL and CSF TDP-43 improves diagnostic performance in ALS. *Annals of*
312 *clinical and translational neurology* 2019;6(12):2489-502.
- 313 15. Ikenaka K, Atsuta N, Maeda Y, Hotta Y, Nakamura R, Kawai K, et al. Increase of
314 arginine dimethylation correlates with the progression and prognosis of ALS.
315 *Neurology* 2019.
- 316 16. Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage
317 markers in cerebrospinal fluid are increased in ALS. *Neurology*
318 2006;66(6):852-6.
- 319 17. Tortelli R, Ruggieri M, Cortese R, D'Errico E, Capozzo R, Leo A, et al. Elevated
320 cerebrospinal fluid neurofilament light levels in patients with amyotrophic
321 lateral sclerosis: a possible marker of disease severity and progression.
322 *European journal of neurology* 2012;19(12):1561-7.
- 323 18. Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, et al.
324 Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis:
325 Neurofilament Light Chain Levels in Definite Subtypes of Disease. *JAMA*
326 *neurology* 2017;74(5):525-32.
- 327 19. Menke RA, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A, et al. CSF
328 neurofilament light chain reflects corticospinal tract degeneration in ALS.
329 *Annals of clinical and translational neurology* 2015;2(7):748-55.
- 330 20. Yamada S, Hashizume A, Hijikata Y, Ito D, Kishimoto Y, Iida M, et al. Ratio of
331 urinary N-terminal titin fragment to urinary creatinine is a novel biomarker for
332 amyotrophic lateral sclerosis. *Journal of neurology, neurosurgery, and*
333 *psychiatry* 2021.

334
335
336

337 **Figures and legends**

338 Figure 1. Increased serum ADMA level in ALS patients and its association with disease
339 progression. (A) Correlation between CSF and serum ADMA levels (n = 68). (B)
340 ADMA concentrations of control patients (n = 54) and ALS patients (n = 68). ** $p <$
341 0.01, Student t -test. (C) Correlation of serum ADMA concentrations and disease
342 progression scores (ALSFRS-R preslope) or disease severity score (ALSFRS-R) (n = 68
343 for both analyses).

344

345 Figure 2. Comparison between serum ADMA level and plasma NfL or CSF NO level.
346 (A) Correlation between serum ADMA concentration and plasma NfL level (n = 51).
347 (B) Correlation between serum ADMA level and plasma NfL level (n = 43).

348

349 Figure 3. Serum ADMA level predicts the prognosis of ALS patients. (A) Kaplan-Meier
350 curve according to serum ADMA level (low: < 110.53 ng/mL, blue line; high: > 110.54 ,
351 red line). Kaplan-Meier curves for the primary endpoint were compared by the logrank
352 test. There was a statistically significant difference between the curves ($p = 0.001$).

353

Figure 1







Figure 2





Figure 3

A

